Evidence map›Paper›PMID 39075721›Full record

Observational studyESC heart failure2024

Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fraction.

Angiza Shahim, Erwan Donal, Camilla Hage, Emmanuel Oger, Gianluigi Savarese, Hans Persson, Ida Haugen-Löfman, Pierre-Vladimir Ennezat, Catherine Sportouch-Dukhan, Elodie Drouet and 4 more

Abstract readObservational StudyMulticenter Study
In one paragraph

Observational study in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Angiza ShahimDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-4574-149X
Erwan DonalDépartement de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Camilla HageDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Emmanuel OgerPharmacoepidemiology and Health Services Research, REPERES, University of Rennes, Rennes, France.
Gianluigi SavareseDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Hans PerssonDepartment of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Ida Haugen-LöfmanDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Pierre-Vladimir EnnezatService de Cardiologie, CHU, Lille, France.
Catherine Sportouch-DukhanDépartement de Cardiologie, CHU Montpellier, Montpellier, France.
Elodie DrouetSociété Française de Cardiologie, Paris, France.
Jean-Claude DaubertDépartement de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.
Cecilia LindeDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Lars H LundDivision of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
KaRen investigators

Funding

Fédération Française de CardiologieFédération Française de Cardiologie/Société Française de CardiologieMedtronic Bakken Research CenterMedtronic Bakken Research Center, Maastricht, the NetherlandsStockholm County Council 00556-2009Stockholm County Council 20090376Stockholm County Council 20110120Stockholm County Council 20110610Swedish Heart Lung Foundation 20080409Swedish Heart Lung Foundation 20080498Swedish Heart Lung Foundation 20100419Swedish Heart Lung Foundation 20110406Swedish Research Council 2013-23897-104604-23
6 · The paper itself

Abstract

aimsThe detailed sub-categories of death and hospitalization, and the impact of comorbidities on cause-specific outcomes, remain poorly understood in heart failure (HF) with preserved ejection fraction (HFpEF). We sought to evaluate rates and predictors of cardiovascular (CV) and non-CV outcomes in HFpEF.

methodsThe Karolinska-Rennes study was a bi-national prospective observational study designed to characterize HFpEF (ejection fraction ≥45%). Patients were followed for cause-specific death and hospitalization. Baseline characteristics were pre-selected based on clinical relevance and potential eligibility criteria for HFpEF trials. The associations between characteristics and cause-specific outcomes were assessed with univariable and multivariable Cox regressions.

resultsFive hundred thirty-nine patients [56% females; median (inter-quartile range) age 79 (72-84) years; NT-proBNP/BNP 2448 (1290-4790)/429 (229-805) ng/L] were included. Over 1196 patient-years follow-up [median (min, max) 744 days (13-1959)], there were 159 (29%) deaths (13 per 100 patient-years: CV 5.1 per 100, dominated by HF 3.9 per 100; and non-CV 5.8 per 100, dominated by cancer, 2.3 per 100). There were 723 hospitalizations in 338 patients (63%; 60 per 100 patient-years: CV 33 per 100, dominated by HF 17 per 100; and non-CV 27 per 100, dominated by lung disease 5 per 100). Higher age and natriuretic peptides, lower serum natraemia and NYHA class III-IV were independent predictors of CV death; lower serum natraemia, anaemia and stroke of non-CV death; and anaemia and lower serum natraemia of non-CV death or hospitalizations. There were no apparent predictors of CV death or hospitalization.

conclusionsIn a clinical cohort hospitalized and diagnosed with HFpEF, death and hospitalization rates were roughly similar for CV and non-CV causes. CV deaths were predicted primarily by severity of HF; non-CV deaths primarily by anaemia and prior stroke. Lower serum sodium predicted both. Hospitalizations were difficult to predict.

Indexed as

Cause of DeathHeart FailureHospitalizationStroke VolumeAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleNatriuretic Peptide, BrainPeptide FragmentsPrognosisProspective StudiesRisk FactorsSurvival RateNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)CardiovascularHeart failure with preserved ejection fractionHospitalizationTrial design

Identifiers

PMID39075721
PMCPMC11631285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.